Kedrion's QIVIGY® Receives Orphan Drug Designation for Rare Neurological Disorder

Kedrion's QIVIGY® Receives Orphan Drug Designation for Stiff Person Syndrome

Kedrion Biopharma has recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its immune globulin intravenous product, QIVIGY®. This designation comes as a significant advancement in the development of treatments for Stiff Person Syndrome (SPS), an ultra-rare neurological disorder that greatly impacts the lives of individuals affected by it.

Understanding Stiff Person Syndrome

Stiff Person Syndrome is characterized by severe muscle stiffness and spasms, making mobility and daily activities exceedingly difficult for those diagnosed. The disorder is estimated to affect around two out of every 100,000 individuals, and its diagnosis often involves delays, particularly as symptoms typically manifest in midlife, between ages 30 and 50. Given the complexity and rarity of the condition, there are currently no FDA-approved therapies specifically for SPS, leaving a vast gap in effective treatment options for patients.

Significance of Orphan Drug Designation

The Orphan Drug Designation provides Kedrion with several incentives to develop QIVIGY® specifically for SPS. These include tax credits, grants to support clinical trials, and seven years of market exclusivity post-approval. This regulatory recognition underscores a growing commitment towards addressing the needs of patients suffering from rare diseases. According to Dr. Nisha Jain, Vice President of Global Clinical Development and Strategy at Kedrion Biopharma, the designation marks an essential step towards providing a much-needed solution for Stiff Person Syndrome.

Current Status of QIVIGY®

Currently, QIVIGY® is approved for use in treating adults diagnosed with primary humoral immunodeficiency. However, its efficacy and safety in the context of SPS are still undergoing rigorous evaluation through clinical trials (NCT 07552987). There exists a feeling of optimism within the medical community regarding the potential of QIVIGY® to significantly affect the progression and functional outcomes of this debilitating condition.

Professor Scott Newsome of the Johns Hopkins Stiff Person Syndrome Center of Excellence expresses hope that the structured trials of QIVIGY® will shed light on how targeted intravenous immunoglobulin therapy can modify disease progression and vastly improve the quality of life for patients. He emphasizes the serious nature of SPS and the profound impact it can have on those suffering, highlighting the need for innovative therapeutic approaches.

Tara Zier, the founder of The Stiff Person Syndrome Research Foundation, speaks to the excitement surrounding the clinical exploration of QIVIGY® specifically for SPS. For too long, individuals within this community have grappled with a harsh reality of limited treatment options and minimal therapeutic development.

Kedrion's Commitment to Rare Diseases

Kedrion Biopharma, a company renowned for its expertise in producing plasma-derived therapies for rare and ultra-rare disorders, has positioned itself as a leader in addressing the needs of underserved patient populations. The company operates globally, employing over 5,400 professionals and collecting plasma in the United States and Czech Republic to produce therapies that aim to improve the lives of patients with conditions such as SPS.

The advancements in the development of QIVIGY® could revolutionize care for individuals with Stiff Person Syndrome and serve as an impetus for further research and therapeutic strategies targeting other rare diseases.

Conclusion

The Orphan Drug Designation for QIVIGY® represents an important milestone for patients afflicted by Stiff Person Syndrome. As clinical trials continue, the hope is that this promising therapy will contribute to a brighter future for many who face the challenges posed by this rare neurological disorder. Kedrion's ongoing commitment to innovation and partnership with the medical community reinforces the belief that science and care can indeed change lives.

For further details on QIVIGY® and updates on its clinical trials, please visit Kedrion Biopharma’s official website.